An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
TandemAI Announces Expansion of Senior Leadership Team
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Positive)
Tags
management
Rhea-AI Summary
TandemAI has appointed Albert Pan, Ph.D., as Chief Technology Officer and Lanny Sun as Chairman of the Board of Directors. Dr. Pan brings over 20 years of experience in molecular simulation and drug discovery, previously at D.E. Shaw Research. Sun is a seasoned executive with a strong biotechnology background, co-founding Silicon Therapeutics, which was acquired by Roivant Sciences in 2021. TandemAI recently completed a $25 million funding round to enhance its recruitment and expand drug discovery operations utilizing AI-based tools.
Positive
Appointment of Albert Pan is expected to enhance technological capabilities in drug discovery.
Lanny Sun's leadership could drive strategic growth and firm development.
Recent $25 million funding round enables rapid talent acquisition.
Integration of AI tools is positioned to improve drug discovery efficiency.
Negative
None.
Albert Pan, Ph.D., named Chief Technology Officer
Lanny Sun appointed Board Chairman
NEW YORK & SUZHOU & SHANGHAI, China--(BUSINESS WIRE)--
TandemAI, a technology company focused on transforming drug discovery infrastructure, today announced two key appointments to its senior leadership team. Albert Pan, Ph.D., has joined the company as Chief Technology Officer and Lanny Sun, Partner and Chief Investment Officer of Gordian Ventures, has joined the board and been named Chairman of the Board of Directors.
Dr. Pan brings more than 20 years of experience applying molecular simulation to fundamental scientific questions and drug discovery, most recently at D.E. Shaw Research, where he served as a Senior Research Scientist for more than 12 years. Dr. Pan will be based in New York and will continue to expand the computational platform team that will develop a broad range of applications for drug discovery. Mr. Sun is a seasoned life science executive with more than a decade of experience and strong track record in biotechnology, most recently at Silicon Therapeutics, which he co-founded and led as CEO through its acquisition by Roivant Sciences (NASDAQ:ROIV) in February 2021.
“Albert and Lanny bring a wealth of technical expertise, and business experience, respectively to TandemAI,” said Jeff He, MBA, co-founder and CEO of TandemAI. “Albert is a leader in computer-aided drug design and molecular dynamics simulation, and he has deep experience using novel computational methods to successfully interrogate difficult targets. We look forward to his many contributions as he advances TandemAI’s computational technology development platform. Lanny has an outstanding track record in company building. His knowledge and insights are extremely valuable to TandemAI’s continued growth.”
He noted that TandemAI recently raised $25 million in Seed and pre-Series A financing, enabling the company to rapidly recruit top talent in both the US and China.
“Small molecule drug discovery is at the front end of a new era of innovation and productivity driven by the emergence of AI-based computational tools,” said Mr. Sun. “TandemAI is integrating dry and wet lab operations to democratize access to advanced computational technology and to provide a turnkey drug discovery solution to partners. I look forward to working with Jeff, Albert and the TandemAI team to realize that vision.”
“TandemAI represents a terrific opportunity, especially at this point in time,” said Dr. Pan. “The need has never been greater for cutting edge computational tools to facilitate faster, more cost-efficient drug discovery against difficult targets, with higher success rates. The scale and ambition of what TandemAI seeks to achieve is truly impressive.”
Dr. Pan earned a Ph.D. in chemistry from the University of California, Berkeley, and an A.B. in chemistry and physics from Harvard University, where he graduated magna cum laude. He was an NIH NRSA Postdoctoral Fellow at the University of Chicago.
In addition to TandemAI and Gordian, Mr. Sun serves as Chairman of Full-Life Technologies, a fully integrated global Nuclear Health company. Prior to Silicon Therapeutics, he served as CEO or Managing Partner at a wide range of healthcare companies and venture capital firms.
About Gordian Ventures
Gordian is global life science venture firm focused on the incubation of companies with extremely high technical barriers to entry. Gordian’s team is comprised of successful entrepreneur operators who focus on being a Co-founder to each of the ventures in which it operates / incubates. Gordian is headquartered in Massachusetts with offices in Shanghai, China.
About TandemAI
TandemAI is an advanced technology company dedicated to reinventing drug discovery infrastructure. The company integrates proprietary AI-driven, high-performance computation with its efficient, large-scale in-house wet lab operations to deliver a turnkey drug discovery solution. TandemAI has built its networked platform from the ground up in China to increase the speed of drug discovery and deliver cost-effective opportunities to its partners and to the global scientific community. Learn more at www.tandemai.com
